These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2014527)

  • 1. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3.
    Dafoe DC; Bromberg JS; Grossman RA; Tomaszewski JE; Zmijewski CM; Perloff LJ; Naji A; Asplund MW; Alfrey EJ; Sack M
    Transplantation; 1991 Apr; 51(4):762-8. PubMed ID: 2014527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cadaveric renal transplantation with quadruple immunosuppression in patients with a positive antiglobulin crossmatch.
    Stratta RJ; Mason B; Lorentzen DF; Sollinger HW; D'Alessandro AM; Pirsch JD; Kalayoglu M; Belzer FO
    Transplantation; 1989 Feb; 47(2):282-6. PubMed ID: 2645713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
    Norman DJ; Shield CF; Barry J; Bennett WM; Henell K; Kimball J; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadaveric renal transplantation in the cyclosporine and OKT3 eras.
    Stratta RJ; D'Alessandro AM; Hoffmann RM; Sollinger HW; Kalayoglu M; Lorentzen DF; Pirsch JD; Belzer FO
    Surgery; 1988 Oct; 104(4):606-15. PubMed ID: 3051470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M; Haschemeyer RH; Riggio RR; Adubor C; Friedman GS; Cheigh JS; Wang JC; Fotino M; Stubenbord WT; Saal SD
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
    Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
    Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients.
    Debure A; Chkoff N; Chatenoud L; Lacombe M; Campos H; Noël LH; Goldstein G; Bach JF; Kreis H
    Transplantation; 1988 Mar; 45(3):546-53. PubMed ID: 3279578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation--a single-center, prospective, randomized study.
    Abramowicz D; Goldman M; De Pauw L; Vanherweghem JL; Kinnaert P; Vereerstraeten P
    Transplantation; 1992 Sep; 54(3):433-7. PubMed ID: 1412723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
    Benvenisty AI; Cohen D; Stegall MD; Hardy MA
    Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
    Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
    J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
    Schulak JA; Mayes JT; Moritz CE; Hricik DE
    Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.